Keytruda (pembrolizumab) - Risk Of Severe Skin Reactions: Stevens-johnson Syndrome And Toxic Epidermal Necrolysis

KEYTRUDA Recall Summary KEYTRUDA (pembrolizumab), a cancer treatment drug, is being recalled across Canada because it carries a risk of severe skin reactions including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. These conditions involve serious blistering and peeling of the skin and mucous membranes. The recall affects all patients in Canada who have been prescribed this medication.

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2017-03-20

Status

Closed

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/6dc3490b-df95-494c-a123-31139b7e4719